A retrospective study of the results of intravenous use of iron carboxymaltosate in a short period of time before cardiac surgery

Aim. To evaluate the results of intravenous use of iron carboxymaltosate in the short term before cardiac surgery in patients with iron deficiency. Materials and methods. The retrospective study included data from the medical records of 113 patients with iron deficiency who underwent cardiac surgery. All patients were divided into two groups depending on the presence (60 people) or absence (53 people) of anemia in the preoperative period. The effect of iron carboxymaltosate infusion on the level of hemoglobin (Hb), ferritin, the need for transfusion of erythrocyte-containing blood components, the duration of the postoperative period, mortality and complications was analyzed. Results. After iron carboxymaltosate infusion, an increase in ferritin levels was noted in group 1 to an average of 536.3±150.4 ng/ml, in group 2 – 640.6±231.5 ng/ml (p=0.7). The increase in Hb levels after iron carboxymaltosate infusion in group 1 averaged 5.1±3.2 g/l, in group 2 – 3.5±5.0g/l (p=0.0428). In the postoperative period group 1 patients received an average of 0.08±0.3 doses of erythrocyte-containing blood components versus 0.1±0.5 doses in group 2 (p=0.97). No deaths were recorded. The duration of treatment in the intensive care unit and the total duration of the postoperative period in both groups did not significantly differ. Surgical bleeding was recorded in 3 patients (5%) of group 1 and 2 patients (3.7%) of group 2 (p=0.372). Infectious complications were detected in 1 patient in each group (p=0.93). Conclusion. The use of a single infusion of iron carboxymaltosate in a short time before cardiac surgery makes it possible to effectively restore ferritin concentration and increase Hb levels in cardiac surgery patients with and without anemia, without affecting the risk of infectious complications and death.